A Phase II, Open-Label, Safety, Efficacy and Pharmacodynamic Study of oral sonidegib in patients with Basal Cell Carcinoma (BCC) and prior exposure to Hedgehog Pathway inhibitors

Trial Profile

A Phase II, Open-Label, Safety, Efficacy and Pharmacodynamic Study of oral sonidegib in patients with Basal Cell Carcinoma (BCC) and prior exposure to Hedgehog Pathway inhibitors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2014

At a glance

  • Drugs Sonidegib (Primary) ; Vismodegib
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Acronyms SALSA
  • Most Recent Events

    • 12 Aug 2014 New trial record
    • 12 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top